お知らせ • Apr 20
co.don AG to Report Q4, 2025 Results on Apr 21, 2026 co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026 お知らせ • Apr 15
co.don AG to Report Q4, 2025 Results on Apr 14, 2026 co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026 お知らせ • Mar 10
co.don AG to Report Q2, 2025 Results on Mar 10, 2026 co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026 お知らせ • Feb 25
co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026 co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026 New Risk • Oct 01
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Market cap is less than US$10m (€657.4k market cap, or US$695.0k). お知らせ • Jan 26
ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW). ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. Breakeven Date Change • Nov 30
Forecast to breakeven in 2023 The analyst covering co.don expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Average annual earnings growth of 114% is required to achieve expected profit on schedule. Price Target Changed • Nov 17
Price target decreased to €6.30 Down from €7.60, the current price target is provided by 1 analyst. New target price is 31,088% above last closing price of €0.02. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €0.20 next year compared to a net loss per share of €0.41 last year. Reported Earnings • Jul 12
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to €5.85 Down from €7.60, the current price target is an average from 2 analysts. New target price is 335% above last closing price of €1.35. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year. Price Target Changed • Feb 01
Price target decreased to €5.85 Down from €7.60, the current price target is an average from 2 analysts. New target price is 252% above last closing price of €1.66. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year. Price Target Changed • Jun 22
Price target increased to €4.20 Up from €3.80, the current price target is an average from 2 analysts. New target price is 200% above last closing price of €1.40. Stock is up 13% over the past year. Reported Earnings • May 06
Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Nov 20
New 90-day high: €1.56 The company is up 30% from its price of €1.20 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.41 per share. Is New 90 Day High Low • Oct 13
New 90-day low: €0.93 The company is down 28% from its price of €1.30 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.53 per share. Is New 90 Day High Low • Sep 25
New 90-day low: €0.99 The company is down 36% from its price of €1.54 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.52 per share.